Home Featured 2

Featured 2

Featured posts

Random

Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s Perspective

lungcanc

Ongoing Clinical Challenges: Defining Immunotherapy Benefit for Patients With NSCLC and Poor Performance Status

Understanding the Effects of Time to Surgery on Upstaging for Stage I Non-Small Cell Lung Cancer

Broad Molecular Testing in Lung Cancer: The Struggle to Translate Recommendations to Clinical Practice

Dr. Jamie E. Chaft Discusses Emerging Data on Induction Immunotherapy for NSCLC

Disparities in Meeting Eligibility Criteria for Lung Cancer Screening

lungcanc

SHAWL: Largest Study of Its Kind Evaluates Sexual Dysfunction in Women...

lungcanc

The Changing the Landscape of Tobacco Products: Potential Effects of ENDS...

lungcanc

PD-L1 in Cytology Specimens

lungcanc

ICU Care for the Patient with Lung Cancer

lungcanc

Adjuvant EGFR-TKI for Resected NSCLC: Who, When, and Where?

lungcanc

PCI Decreases the Risk of Brain Metastases in Patients with Locally...

lungcanc

Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in...

lungcanc

Pembrolizumab Considered for Second Tissue-Agnostic Cancer Indication

lungcanc

A Roadmap to Improving Lung Cancer Care in the Middle East...

lungcanc

12 3...7 Page 1 of 7

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib